Completed PHASE3 INTERVENTIONAL 2-arm NCT00480896

Treatment and Control of Atopic Dermatitis With 0.03% Tacrolimus Ointment

Clinical Study on Tacrolimus Ointment Over the Long-term. CONTROL Study - Children

Sponsor: Astellas Pharma Inc

Interventions Placebo ointment tacrolimus ointment

Updated 7 times since 2017 Last updated: Sep 17, 2014 Started: Jun 30, 2004 Primary completion: Nov 30, 2005 Completion: Nov 30, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00480896, this PHASE3 trial focuses on Dermatitis, Atopic and remains completed. Sponsored by Astellas Pharma Inc, it has been updated 7 times since 2004, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Jun 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Astellas Pharma Inc

Data source: Astellas Pharma Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amsterdam, Netherlands , Barcelona, Spain , Bergamo, Italy , Birmingham, United Kingdom , Brno, Czechia , Brussels, Belgium , Budapest, Hungary , Düsseldorf, Germany , Frankfurt, Germany , Groningen, Netherlands and 12 more locations